STOCK TITAN

Kiniksa accounting chief sells 11,280 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) Chief Accounting Officer Michael R. Megna exercised options for 11,280 Class A ordinary shares at an exercise price of $17.76 per share on November 9, 2026, then sold the same number at a weighted average $98.54 per share. Both transactions were effected under a Rule 10b5-1 plan executed July 30, 2026. Following the exercise, 5,114 share options remained; the options expire August 31, 2033.

Insider Megna Michael R
Role CHIEF ACCOUNTING OFFICER
Sold 11,280 shs ($1.11M)
Approx. gross sale proceeds $1.11M
Approx. exercise cost $200K
Approx. pre-tax spread $911K
Type Security Shares Price Value
Exercise Share Option F1, F3 11,280 $0.00 $0.00
Exercise Class A Ordinary Share F1 11,280 $17.76 $200K
Sale Class A Ordinary Share F1, F2 11,280 $98.54 $1.11M
Holdings After Transaction: Share Option — 5,114 options (Direct); Class A Ordinary Share — 12,697 shares (Direct)
Footnotes (3)
  1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.
  2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $98.48 and $98.64. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. F3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
Options exercised 11,280 options November 9, 2026
Exercise price $17.76 per share Options exercised November 9, 2026
Shares sold 11,280 shares November 9, 2026
Weighted average sale price $98.54 per share November 9, 2026
Options remaining 5,114 options After the November 9, 2026 exercise
Option expiration August 31, 2033 Expiration date of the exercised option grant
Rule 10b5-1 plan regulatory
"transactions effected pursuant to a Rule 10b5-1 plan executed July 30, 2026"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sales price financial
"the reported price reflects a weighted average sales price"
vesting commencement date technical
"the vesting commencement date is September 1, 2023"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares did Michael R. Megna sell and at what price?

Michael R. Megna sold 11,280 Class A ordinary shares at a weighted average price of $98.54 per share. The sale was made under a Rule 10b5-1 plan executed July 30, 2026, through multiple broker-dealer trades at prices ranging from $98.48 to $98.64.

How many KNSA options remained after Michael R. Megna's exercise?

5,114 share options remained after the November 9, 2026 exercise. The options expire August 31, 2033.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Megna Michael R

(Last)(First)(Middle)
C/O KINIKSA PHARMACEUTICALS INT'L
105 PICCADILLY, SECOND FLOOR

(Street)
LONDONW1J 7NJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF ACCOUNTING OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Share11/09/2026M(1)11,280A$17.7623,977D
Class A Ordinary Share11/09/2026S(1)11,280D$98.54(2)12,697D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option$17.7611/09/2026M(1)11,280 (3)08/31/2033Class A Ordinary Share11,280$05,114D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $98.48 and $98.64. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
/s/ Douglas Barry, Attorney-in-Fact11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading